SAL0112, a novel small-molecule biased GLP-1 receptor agonist, showed potent and selective Gαs pathway activation without desensitization, greater metabolic stability than danuglipron, and comparable efficacy to liraglutide in reducing body weight, blood glucose, and liver fat in diabetic mice.
No receptor desensitizationUnlike many GLP-1 agonists that lose effectiveness over time as receptors become desensitized, SAL0112 maintained full potency — a potential advantage for long-term treatment
What the researchers found
SAL0112 demonstrated potent selective Gαs pathway GLP-1R activation without desensitization. Superior stability vs danuglipron in human/rat liver microsomes. Higher oral absorption in rats. Lower DDI potential on liver transporters vs danuglipron. Significant reductions in body weight, blood glucose (p<0.05), HbA1c (p<0.05), and insulin resistance (p<0.01) in diabetic mice. Resolved hepatic steatosis. Efficacy comparable to danuglipron and liraglutide.
Why it matters
Most GLP-1 drugs are injectable peptides. The race to develop effective oral GLP-1 drugs is intense, with oral semaglutide being the only approved option. SAL0112 represents a new approach — biased agonism — that could offer better tolerability and fewer side effects while maintaining efficacy as an oral medication.
The numbers in context
Tested across multiple assay platforms. Liver transporter interactions assessed. Stability tested across multiple species.
How the study worked
In vitro: HTRF, FLIPR, TR-FRET, and PathHunter assays for receptor pharmacology. Liver transporter tests in HEK293-OATP1B1/1B3 cells. Stability in multi-species liver microsomes. In vivo: PK in rats; efficacy in high-fat diet transgenic C57BL/6 mice expressing human GLP-1R.
Who was studied
In vitro receptor studies and multi-species pharmacokinetics
What this study cannot tell us
Preclinical data only — no human studies. Transgenic mice expressing human GLP-1R don't fully predict human pharmacology. Direct comparison with oral semaglutide (the current market leader) was not performed. Long-term safety and tolerability unknown.
How to read the evidence
Rated preliminary: comprehensive preclinical characterization but no human data. The transgenic mouse model adds translational value but clinical trials are needed.
When this study was published
Published in 2024. Part of the active race to develop next-generation oral GLP-1 drugs.
The bigger picture
The oral GLP-1 drug market is projected to be worth tens of billions. SAL0112 represents the 'biased agonism' approach — selectively activating beneficial pathways while avoiding those that cause nausea and other side effects. If this translates to humans, it could be a major advance in the GLP-1 space.
Questions still open
- Does biased Gαs agonism actually reduce GLP-1 side effects (nausea, vomiting) in humans?
- How does SAL0112 compare to oral semaglutide in head-to-head testing?
- Will the superior metabolic stability translate to better oral bioavailability in humans?
Common questions
What makes SAL0112 different from existing GLP-1 drugs?
Could this replace injectable GLP-1 drugs like Ozempic?
Read the original research
Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 177, 116965
Citation
Sun, Jingchao; Xiao, Ying; Xing, Wei; Jiang, Wenjuan; Hu, Xuefeng; Li, Hongchao; Liu, Zhaojun; Jin, Qian; Ren, Peng; Zhang, Hongmei; Lobie, Peter E. (2024). Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 177, 116965. https://doi.org/10.1016/j.biopha.2024.116965